Free Newsletter
Biogen posts 50% growth in profits
Free newsletter via e-mail
Tools
Biogen Idec's first-quarter profits jumped 50 percent to $244 million on higher sales of its multiple sclerosis drug Avonex; revenues grew by a healthy 10 percent to $1.04 billon, and EPS beat analysts' estimates. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: